We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GAO Downgrades Rating of FDA’s Action Plans for Postmarket Drug Monitoring and Shortages
GAO Downgrades Rating of FDA’s Action Plans for Postmarket Drug Monitoring and Shortages
In its latest biennial report to Congress on high-risk government programs, the GAO downgraded its rating of the FDA’s action plans, saying CDER, CBER and CDRH’s long-term strategies lack adequate details and performance measures.